Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A randomised double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration.

Literature DB >> 7044411

A randomised double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration.

Abstract

A double-blind clinical trial of 3% acyclovir (Zovirax) and 3% adenosine arabinoside (ara-A, Vidarabine) in 93 patients with herpetic corneal ulceration is presented. Ulcers in 45 (94%) of acyclovir-treated patients and 37 (82%) ara-A-treated patients healed within 14 days. Patients treated with acyclovir healed more rapidly than those treated with ara-A (p less than 0.01). No serious adverse effects were observed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1982 PMID： 7044411 PMCID： PMC1039800 DOI： 10.1136/bjo.66.6.361

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

10 in total

1. 9-BETA-D-ARABINOFURANOSYLADENINE AS AN INHIBITOR OF METABOLISM IN NORMAL AND NEOPLASTIC CELLS.

Authors: J J BRINK; G A LEPAGE
Journal: Can J Biochem Date: 1965-01

2. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors: J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal: J Biol Chem Date: 1978-12-25 Impact factor: 5.157

3. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors: G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal: Proc Natl Acad Sci U S A Date: 1977-12 Impact factor: 11.205

4. A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.

Authors: D Pavan-Langston; C H Dohlman
Journal: Am J Ophthalmol Date: 1972-07 Impact factor: 5.258

5. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis.

Authors: J P Travers; A Patterson
Journal: J Int Med Res Date: 1978 Impact factor: 1.671

6. A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis.

Authors: D J Coster; K R Wilhelmus; R Michaud; B R Jones
Journal: Br J Ophthalmol Date: 1980-10 Impact factor: 4.638

7. Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers.

Authors: J McGill; P Tormey; C B Walker
Journal: Br J Ophthalmol Date: 1981-09 Impact factor: 4.638

8. Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

Authors: L M Collum; A Benedict-Smith; I B Hillary
Journal: Br J Ophthalmol Date: 1980-10 Impact factor: 4.638

9. Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers.

Authors: B R Jones; D J Coster; P N Fison; G M Thompson; L M Cobo; M G Falcon
Journal: Lancet Date: 1979-02-03 Impact factor: 79.321

10. Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial.

Authors: C la Lau; J A Oosterhuis; J Versteeg; G van Rij; J G Renardel de Lavalette; A Craandijk; W R Lamers; T Mierlobensteyn
Journal: Doc Ophthalmol Date: 1981-03-20 Impact factor: 2.379

10 in total

Review 1. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors: Kirk R Wilhelmus
Journal: Cochrane Database Syst Rev Date: 2015-01-09

2. A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis.

Authors: S M Porter; A Patterson; P Kho
Journal: Br J Ophthalmol Date: 1990-05 Impact factor: 4.638

3. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors: C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal: Antimicrob Agents Chemother Date: 1996-05 Impact factor: 5.191

A randomised double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration.

1. 9-BETA-D-ARABINOFURANOSYLADENINE AS AN INHIBITOR OF METABOLISM IN NORMAL AND NEOPLASTIC CELLS.

2. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

3. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

4. A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.

5. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis.

6. A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis.

7. Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers.

8. Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

9. Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers.

10. Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial.

Review 1. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

2. A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis.

3. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

4. The treatment of herpes simplex virus epithelial keratitis.

Review 5. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

6. Oral acyclovir in the management of dendritic herpetic corneal ulceration.

7. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration.

8. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.

9. Acyclovir (Zovirax) in herpetic disciform keratitis.

Review 10. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.